Study results support the indication of glecaprevir/pibrentasvir as the first 8-week pangenotypic treatment option for HCV/HIV-1 coinfected patients without cirrhosis.
Katie Burk, MPH, presented measures undertaken by the city of San Francisco to provide integrated responses to the concurrent HIV/HCV and opioid public health epidemics.
More comprehensive research will be needed to further investigate cerebrospinal fluid p24 by high-sensitivity assay as a marker for neurocognitive impairment during poorly controlled HIV and as a marker for HIV central nervous system reactivation during latency reversal therapy.
Generic antiretroviral agents have had a dramatic effect on outcomes in developing nations, and their availability in developed countries is rapidly expanding as more brand-name drugs are coming off patent. But unique challenges surrounding their use remain.
Interventions for diabetes prevention and management may be needed to reduce the risk for diabetes in patients with HIV.
About half of pregnant women with HIV infection underwent cesarean delivery between 1998 and 2013.
The absence of availability of amphotericin B or in conditions in which amphotericin B cannot be administered safely, the oral combination of fluconazole plus flucytosine provides an effective and sustainable alternative.
The HR-HPV types covered by the nonavalent HPV vaccine had similar clearance rates to HR-HPV types not included, and women infected with multiple anogenital HR-HPV types had lower rates of clearance than women infected with only 1 type.
Researchers assessed the differential risk of acquiring HIV-1 infection across reproductive stages by calculating per-coital-act risk for each stage and comparing with nonpregnant times.
Investigators assessed adherence to antiretroviral therapy, retention in care, and virologic outcomes in patients receiving once-daily single-tablet and multiple-tablet antiretroviral therapy regimens.
The effects of a peer navigation intervention on HIV viral suppression in previously incarcerated individuals were examined.
A head-to-head comparison was made between HIV-1 treatment regimens containing tenofovir alafenamide plus emtricitabine with those containing abacavir plus lamivudine.
Text messaging may be a promising strategy for support and engagement in HIV care.
The rapidly developing landscape of antiretroviral therapy adherence monitoring has great potential for clinical application, but cost-effectiveness and feasibility studies are needed to define the appropriate roles for these new technologies.
Investigators sought to determine the association between antiretroviral therapy and cytomegalovirus infection in individuals with HIV, as well as the potential impact of both on neurocognitive performance.
HIV-positive patients with pulmonary tuberculosis benefited from daily antituberculosis therapy in terms of effectiveness and rifampicin resistance.
The Copenhagen Co-morbidity in HIV Infection (COCOMO) study assessed the association between risk factors for cardiovascular disease and HIV infection.
Certain HIV symptoms, especially fatigue, muscle aches, may be worsened with menopause.
Symfi contains the same triple combination ingredients found in the recently approved and launched Symfi Lo but with a 600mg dose of efavirenz vs 400mg seen in Symfi Lo.
Access to prevention methods, such as condoms and preexposure prophylaxis, is needed, particularly among MSM of color and young MSM.
More research is needed to better capture the interplay between prediabetes/diabetes and antiretroviral therapy in people with HIV.
Overall HIV incidence in the United States has decreased in all high-risk transmission groups except for minority men who have sex with men.
Connecting young Black MSM and transgender women to the best test option, given preferences for specific characteristics, may support more and more consistent HIV testing.
Findings from this phase 4 study call for a re-evaluation of the current WHO and CDC guidelines of isoniazid preventive therapy for the prevention of tuberculosis in pregnant women with HIV.
Interim results from this open-label extension trial of the dapivirine ring demonstrate high uptake and adherence, and HIV-1 incidence has been half of the expected rate.
Study confirms HPV16 as an important determinant of high-grade lesions and supports its place as a priority for anal cancer prevention.
A phase 3 study evaluating HIV patients who switched to treatment with Biktarvy found this combination therapy to be statistically noninferior to a regimen containing abacavir,
Study evaluated the association between the concentrations of specific vaginal bacteria and increased risk for HIV acquisition in African women.
The FDA has approved Trogarzo for the treatment of adults with HIV whose infections are multidrug-resistant.
A novel method - Antibody Detection by Agglutination-PCR (ADAP) - was developed to diagnose HIV in oral fluid samples. ADAP is both highly sensitive and highly specific and may allow noninvasive early diagnosis of HIV in population-based screening efforts.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Generic HIV Medicines: Boon or Bust?
- Insulin-Treated Diabetes Reduces Dysglycemia-Related Mortality in Sepsis
- It Costs $2.2 Billion a Year to Treat Antibiotic Resistance
- Tricyclic Antidepressants May Reduce Cirrhosis Risk in Hepatitis C
- Pregnancy May Be Independently Associated With Prolonged Detection of Zika Virus RNA
- Clostridium difficile Infection in the Intensive Care Setting
- Combating Medically Important Antibiotic Use in Food-Producing Animals
- Religious Exemptions vs Mandatory Vaccinations: An Expert Perspective
- 2018 Vaccination Schedule: Adults
- Fingerstick Point-of-Care Test Allows for Single-Visit HCV Diagnoses
- Glecaprevir/Pibrentasvir Highly Efficacious for HCV/HIV Coinfection
- Fluoroquinolone Use May Increase Risk for Aortic Aneurysm and Dissection
- Reduced Risk of Hepatocellular Carcinoma in DAA-Treated HCV Infection
- Paracetamol Overuse During Cold and Flu Season
- C difficile Risk Higher With Stoma Reversal vs Colectomy